News of Novavax’s successful production of an H1N1 vaccine using new technology isn’t a major surprise. However, a press release from ten years ago, almost to the day, piques one’s curiosity regarding the source (and the money, if not the intent) behind some of Novavax’s breakthroughs: COLUMBIA, Md., Aug. 11Continue Reading